The US Food and Drug Administration has granted breakthrough therapy designation for United Kingdom-based GlaxoSmithKline's meningitis B vaccine, Bexsero [Meningococcal group B Vaccine (rDNA, component, adsorbed)], it was reported yesterday.
The approval is intended for the development of the vaccine in the prevention of Invasive Meningococcal Disease caused by serogroup B in children 2-10 years of age. It is the first vaccine in the world to receive the Breakthrough Therapy Designation twice.
GSK Vaccines chief scientist, Rino Rappuoli, said, 'This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology. GSK is committed to the pursuit of innovative vaccines that help protect against serious diseases with significant unmet need.'
Bexsero is licensed in more than 35 countries.
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15